"All cancers in this study were identified with MR spectroscopy. There were no false-negative results," said Lia Bartella, M.D., lead investigator and assistant professor in the Department of Breast Imaging at Memorial Sloan-Kettering. "With the addition of MR spectroscopy to our breast MRI exam, we found that the number of biopsies recommended on the basis of MRI findings decreased significantly. These results should encourage more women to take this potentially life-saving test."
MRI is playing an increasingly important role in the screening of women at high risk for breast cancer. One drawback of the technology, however, has been a considerable number of breast biopsy procedures recommended on the basis of imaging findings, which turn out to be benign. With MR spectroscopy, the radiologist is able to see the chemical make-up of a tumor, so in most cases, he or she can tell without biopsy whether or not the lesion is cancerous.
"Breast tumors have elevated levels of choline compounds, which are a marker of an active tumor," Dr. Bartella said. "By performing a brief MR spectroscopy procedure after an MRI scan, which takes only 10 additional minutes, we can noninvasively see which tumors show elevated choline levels, and therefore which lesions are likely malignant. This eliminates the need for biopsy to find out what the tumor is made of."
In Dr. Bartella's study, 56 patients with 57 breast lesions underwent MRI first, followed by MR spectrosc
'"/>
Contact: Heather Babiar
hbabiar@rsna.org
630-590-7762
Radiological Society of North America
30-May-2006